SPRC SciSparc Ltd.

Nasdaq scisparc.com


$ 2.38 $ -0.11 (-4.47 %)    

Thursday, 20-Nov-2025 15:38:40 EST
QQQ $ 585.94 $ -14.20 (-2.37 %)
DIA $ 458.27 $ -3.66 (-0.79 %)
SPY $ 652.87 $ -10.10 (-1.52 %)
TLT $ 89.25 $ 0.35 (0.39 %)
GLD $ 374.61 $ -0.11 (-0.03 %)
$ 2.35
$ 2.50
$ 2.32 x 131
$ 2.44 x 100
$ 2.35 - $ 2.35
$ 1.75 - $ 37.59
26,610
na
79,081
$ 1.25
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
No Data found
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

Core News & Articles

SciSparc Ltd. (NASDAQ:SPRC) ("Company" or "SciSparc"), today announced that NeuroThera Labs Inc. (TSXV:NTLX) (&...

Core News & Articles

Clearmind Medicine Inc. (NASDAQ:CMND), (FSE: CWY0) ("Clearmind" or the "Company"), a clinical-stage biotech com...

Core News & Articles

N2OFF, Inc. (NASDAQ:NITO) ("N2OFF" and the "Company"), a cleantech company investing in solar energy assets bas...

Core News & Articles

SciSparc Ltd. (NASDAQ:SPRC) ("Company" or "SciSparc"), a specialty clinical-stage pharmaceutical company focusi...

Core News & Articles

Clearmind Medicine Inc. (NASDAQ:CMND), (FSE: CWY0) ("Clearmind" or the "Company"), a clinical-stage biotech com...

 scisparc-expands-biotech-ambitions-buys-stake-in-miza-iii-ventures

SciSparc traded higher after the company announced it had signed a definitive agreement to acquire a controlling stake in Miza ...

Core News & Articles

SciSparc Ltd. (NASDAQ:SPRC) ("Company" or "SciSparc"), a specialty clinical-stage pharmaceutical company focusi...

 scisparc-and-automax-call-off-merger

SciSparc ends merger with AutoMax, sets loan repayment terms, and refocuses on CNS drug development and innovation.

 scisparc-terminates-automax-merger-secures-625m-repayment-plan-with-structured-interest-terms

SciSparc Ltd. (NASDAQ:SPRC) (the "Company" or "SciSparc"), a specialty clinical-stage pharmaceutical company fo...

Core News & Articles

Gainers SciSparc (NASDAQ: SPRC) shares increased by 28.2% to $5.68 during Monday's after-market session. The company's...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION